About Influx Healthtech Limited
Influx Healthtech Limited, incorporated in September 2020, is an emerging Contract Development and Manufacturing Organization (CDMO) with a stronghold in the nutraceuticals, cosmetics, ayurvedic, and veterinary supplement sectors. Headquartered in Maharashtra, the company operates three state-of-the-art manufacturing units spread across Thane, covering 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. respectively.
With a wide-ranging product portfolio that includes tablets, capsules, softgels, jellies, gummies, oral dispersible films, skincare and haircare products, the company caters to clients across various industries. Their offerings also include ayurvedic/herbal formulations, veterinary feed supplements, and homecare solutions.
Influx Healthtech stands out for its end-to-end CDMO services from R&D to manufacturing and regulatory support allowing clients to focus on brand building and distribution while relying on Influx for consistent quality and innovation. As of June 2025, the company employs 163 permanent staff and is led by an experienced team with strong technical expertise and operational excellence.
Why To Invest in Influx Healthtech Limited
Rapidly Growing Sector Exposure : The company operates in the booming sectors of nutraceuticals, cosmetics, herbal products, and veterinary health, which are witnessing strong demand post-COVID and a rising focus on wellness.
Strong Financial Performance : With a 19% YoY growth in PAT and over 104 crore in revenue for FY25, the company demonstrates strong operational performance and profitability.
High Return Ratios : Impressive metrics such as ROE of 36.98% and ROCE of 49.17% highlight effective capital utilization and strong business fundamentals.
Low Leverage : With a debt-to-equity ratio of just 0.01, Influx operates with minimal financial risk and a healthy balance sheet.
Diversified Product & Client Portfolio : The company's offerings range across human health, veterinary care, cosmetics, and homecare catering to a broad and stable demand base.
Purposeful IPO Fund Utilization : The IPO proceeds are focused on capacity expansion, including new manufacturing units for the nutraceutical and veterinary divisions, ensuring future scalability.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 70.30 | 41.10 | 28.30 |
| Revenue | 104.99 | 100.10 | 76.07 |
| Profit After Tax | 13.37 | 11.22 | 7.20 |
| Net Worth | 36.15 | 22.87 | 11.65 |
| Reserves and Surplus | 18.00 | 22.85 | 11.63 |
| Total Borrowing | 0.22 | 0.32 | 0.80 |
Explore Other Products
